TriLink Announces New License Agreement with Biofortuna
News Nov 08, 2013
TriLink BioTechnologies, Inc. (TriLink) has announced that it has signed a new licensing agreement with Biofortuna Ltd. (Biofortuna) for use of its CleanAmp™ dNTPs in Biofortuna’s freeze-drying (lyophilized) contract development and production service.
In 2010 Biofortuna licensed TriLink’s CleanAmp™ dNTPs for use in their unique molecular diagnostic kits, SSPGo™, which are now distributed exclusively by Abbott Molecular for the HLA, transplantation, disease ID and PGx market.
The expanded CleanAmp™ license gives Biofortuna the right to incorporate CleanAmp™ dNTPs into their recently-launched freeze-drying molecular diagnostic kit development and production service.
When developing SSPGo™ (complete freeze dried PCR reaction kits stabilized at ambient temperatures for up to 16 months) CleanAmp™ dNTPs gave Biofortuna a viable Hot Start PCR alternative that improved specificity by simple replacement of standard dNTPs with CleanAmp™ dNTPs.
Now the advantages of these combined technologies are available to all diagnostic kit developers.
At the upcoming Association of Molecular Pathology (AMP) Annual Meeting, TriLink and Biofortuna will host a corporate workshop entitled “Freeze Dried Hot Start PCR Mixes - The Evolution of Molecular Diagnostics.”
This presentation will provide detailed information on each technology and how they come together through Biofortuna’s freeze dried kit development and production service to provide a superior molecular diagnostic product.
Dr. Mike Bunce, Biofortuna CSO commented, “We are delighted to have extended our agreement with TriLink which allows Biofortuna to offer hot start lyophilized mixes to diagnostic companies looking to develop stabilized molecular diagnostic kits.”
“Biofortuna’s continued breakthroughs in lyophilized assay development further highlight the versatility of CleanAmp™ dNTPs as an easy-to-use Hot Start reagent,” said Dr. Natasha Paul, TriLink Sr. Scientific Investigator.
“Biofortuna’s great success with their SSPGo™ product represents to us the real impact the CleanAmp™ technology can have on the evolution of molecular diagnostics. We’re very pleased that Biofortuna’s new lyophilized contract service business will provide an easy path for other kit developers to realize the advantages of CleanAmp™,” said TriLink CEO, Dr. Richard Hogrefe.